FDA sends warning letter to literal snake oil salesman
NutraPharma claimed its cobra venom products could treat chronic pain for conditions ranging from cancer to addiction.
News
Five things for pharma marketers to know: Friday, March 22, 2019
Biogen ends Alzheimer’s trials; CVS starts selling CBD products; 70% say government spends too little on healthcare.
The Escalator: Novocure, NGM name chief medical officers
Plus: Elizabeth Renz to lead global oncology comms at GlaxoSmithKline.
New Greater Than One creative chief Ross Thomson on merging creative and tech
Thomson joined the firm in late February.
Five things for pharma marketers to know: Thursday, March 21, 2019
Novo submits diabetes pill for ‘priority review’; Top FDA compounding staffer to exit; Roman launches women’s product
ePharma: Advances in tools like machine learning will change healthcare marketing
Experts discussed artificial intelligence and machine learning at the ePharma Impact conference in New York on Wednesday.
ePharma: Think outside the box as regulations change, but keep legal in the loop
Marketing and regulatory experts talked about how pharma can keep up with other industries and stay within the lines of the federal regulations.
Fishawack Group acquires rare disease specialist firm Dudnyk
The acquisition represents the U.K. health network’s third in the U.S.
W2O at SXSW 2019: Technology readies to overhaul healthcare ecosystem
During W2O’s partner programming at South by Southwest 2019, speakers examined technology’s impact – both present and future – on the healthcare ecosystem, as the various stakeholders pursue better outcomes for patients.
Five things for pharma marketers to know: Wednesday, March 20, 2019
Sanofi begins CEO succession plan; FDA places partial hold on Venclexta cancer trials; One-third of uninsured patients reduce costs by not taking medicine as prescribed.
Want to read more?
Please login or register first to view this content.
